Top Markets
#1 Islamic Coin Islamic Coin +155.91%
#2 Siren Siren +36.54%
#3 Arowana Arowana +21.82%
#4 Venom Venom +18.20%
#5 Cysic Cysic +16.72%
#6 Nockchain Nockchain +16.48%
#7 RedStone RedStone +16.02%
#8 OpenEden OpenEden +14.76%
#9 Perle Perle +13.17%
#10 KUB Coin KUB Coin +12.50%
Coin of the day
Islamic Coin Islamic Coin
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Brainstorm Cell Therapeutics Inc. Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc.

BCLI
Rang in Aktien #31762
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to... Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.
Aktienkurs
$1.10
Zuletzt synchronisiert: 2026-08-17
Marktkapitalisierung
$12.14M
Veränderung (1 Tag)
11.11%
Veränderung (1 Jahr)
77.42%
Land
US
Handel Brainstorm Cell Therapeutics Inc. (BCLI)

Kategorie

Healthcare
Operative Marge für Brainstorm Cell Therapeutics Inc. (BCLI)
Operative Marge zum 2026 TTM: 0.00%
Laut den neuesten Finanzberichten und dem Aktienkurs von Brainstorm Cell Therapeutics Inc. beträgt die aktuelle operative Marge (TTM) 0.00%. Am Ende des Jahres 2026 lag die operative Marge bei 0.00%.
Historie der operativen Marge von Brainstorm Cell Therapeutics Inc. von 2026 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
Nicht genügend Daten für die angegebenen Daten.
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.